Triphosphate

Triphosphate

SCHEMBL502620

Nc1ncnc2nc[nH]c12.O=P(O)(O)OP(=O)(O)OP(=O)(O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.65
PI4K2B Q8TCG2 2/20 0.65
PI4K2A Q9BTU6 2/20 0.65
PI4KB Q9UBF8 2/20 0.65
LRRK2 Q5S007 2/20 0.65
LMNA P02545 2/20 0.65
DRD3 P35462 1/20 0.65
XDH P47989 1/20 0.65
PDPK1 O15530 3/20 0.41
GDA Q9Y2T3 1/20 0.39
G6PD P11413 1/20 0.39
BRD4 O60885 4/20 0.38
ENPP1 P22413 1/20 0.38
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
CHEK2 O96017 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
PRKACA P17612 1/20 0.37
CCNE1 P24864 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triphosphate SCHEMBL29941501 1.00 PI4KA (0.65) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL29843997 0.99 PI4KA (0.63) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL1035725 0.94 PI4KA (0.69) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL29873138 0.88 PI4KA (0.79) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL29548028 0.88 PI4KA (0.79) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL17046873 0.88 PI4KA (0.79) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL283729 0.88 PI4KA (0.79) PI4KAPI4K2BPI4K2API4KBLRRK2
Adenine SCHEMBL29687975 0.88 PI4KA (0.79) PI4KAPI4K2BPI4K2API4KBLRRK2
Triphosphate SCHEMBL10336169 0.84 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBLRRK2
Triphosphate SCHEMBL19057041 0.82 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596713-A1 DNA WITH ENHANCED RESISTANCE AGAINST EXONUCLEASES AND METHODS FOR THE PRODUCTION THEREOF 4basebio UK Ltd (GB) 2025-08-06 EP claimed
CN-119614709-A Detection method and application of whole genome 5-hydroxymethylcytosine 青岛科技大学 2025-03-14 CN claimed
WO-2024250923-A1 CHEMICALLY MODIFIED NUCLEOSIDE, CHEMICALLY MODIFIED NUCLEOSIDE TRIPHOSPHATE AND USE THEREOF 中国科学院深圳先进技术研究院 2024-12-12 WO claimed
US-20240350027-A1 Methods and Apparatus for Benchtop Metabolite Profiling in Situ VIBO HEALTH INC (US) 2024-10-24 US claimed
EP-4436358-A1 PROCESSES AND SYSTEMS FOR INCREASING DRY MATTER IN HYDROPONICALLY GROWN CELLULOSIC MATERIALS Hydrogreen, Inc. (CA) 2024-10-02 EP claimed
WO-2023096635-A1 PROCESSES AND SYSTEMS FOR INCREASING DRY MATTER IN HYDROPONICALLY GROWN CELLULOSIC MATERIALS HYDROGREEN, INC (CA) 2023-06-01 WO claimed
US-20230157229-A1 PROCESSES AND SYSTEMS FOR INCREASING DRY MATTER IN HYDROPONICALLY GROWN CELLULOSIC MATERIALS Hydrogreen, Inc. (CA) 2023-05-25 US claimed
CN-111505284-B Test paper strip and sensor for detecting novel coronavirus SARS-CoV-2, and preparation and application thereof 中国科学院重庆绿色智能技术研究院 2023-05-02 CN claimed
WO-2023022997-A1 METHODS AND APPARATUS FOR BENCHTOP METABOLITE PROFILING IN SITU ViBo Health Inc. (US) 2023-02-23 WO claimed
US-20220275028-A1 Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins NATURE'S TOOLBOX, INC. 2022-09-01 US claimed
US-20050266508-A1 Detection of potassium ions using ion-sensitive enzymes DIAZYME LABORATORIES, INC. 2005-12-01 US claimed
WO-2005029038-A2 DETECTION OF POTASSIUM IONS USING ION-SENSITIVE ENZYMES GENERAL ATOMICS (US) 2005-03-31 WO claimed
US-20050069970-A1 Detection of potassium ions using ion-sensitive enzymes GENERAL ATOMICS 2005-03-31 US claimed
US-20030212006-A1 Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals BIONERGY, INC. 2003-11-13 US claimed
EP-1032700-A1 SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES New York Medical College (US) 2000-09-06 EP claimed
CN-1049246-C Method for preparing powder type culture-medium of animal cell KANGDA AMINO ACID FASTORY SHAN (CN) 2000-02-09 CN claimed
WO-1999006592-A9 SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES NEW YORK MEDICAL COLLEGE (US) 1999-05-06 WO claimed
WO-1999006592-A1 SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES NEW YORK MEDICAL COLLEGE (US) 1999-02-11 WO claimed
US-5654142-A Method for nucleic acid amplification using inosine triphosphates to partially replace guanosine triphosphates in the synthesis of multiple RNA copies AKZO NOBEL N.V. (NL) 1997-08-05 US claimed
EP-0147713-A2 Enzymatic ATP and FMN assay Miles Italiana SpA (IT) 1985-07-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220275028-A1 Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins MRPL21, RNGTT, MRPS23 PI4KA 3291/4885PI4K2B 2668/4885PI4K2A 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.